ALK and NSCLC: Targeted therapy with ALK inhibitors

F1000 Medicine Reports

Volumn 3, Issue 1, 2011, Pages

  Hallberg, Bengt ^a   Palmer, Ruth H ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 39; AF 802; ANAPLASTIC LYMPHOMA KINASE; AP 26113; ASP 3026; CARBOPLATIN; CEP 28122; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; F 91873; F 91874; GSK 1838705A; HYBRID PROTEIN; K RAS PROTEIN; LDK 378; LKD 978; NMS E628; NVP TAE 684; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; RETASPIMYCIN; SJ 08 0025; UNCLASSIFIED DRUG; X 376; X 396; XALKORI;

CANCER SURVIVAL; CRYSTAL STRUCTURE; DIARRHEA; DNA LIBRARY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; GENE TRANSLOCATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LARGE CELL CARCINOMA; LARGE CELL LYMPHOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOMA; NAUSEA; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SMOKING; VISUAL DISORDER;

EID: 80655126743     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M3-21     Document Type: Review

References (68)

1. American Cancer Society: Global Cancer Facts & Figures, 2nd Edition. Atlanta: American Cancer Society; 2011.
2. TravisWD, Brambilla E, Müller-Hermelink HK, Harris CC: World Health Organisation Classification of Tumors: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: International Agency for Research on Cancer (IARC) Press; 2004.
3. Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK, West DW: Lung cancer incidence in never smokers. J Clin Oncol 2007, 25:472-8. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
4. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-500. F1000 Factor 25 Evaluated by Ruth Palmer 14 Oct 2011, Charles Brenner 02 Dec 2004, Alfred Wittinghofer 15 Sep 2004, Charles Streuli 01 Jul 2004, Joachim Herz 27 May 2004, Patricia C Weber 14 May 2004, William Kaelin 10 May 2004.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-39. F1000 Factor 19 Evaluated by Ruth Palmer 14 Oct 2011, Charles Brenner 02 Dec 2004, Michael B Yaffe 03 Jun 2004, Joachim Herz 27 May 2004, William Kaelin 10 May 2004.
6. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A: Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011, 364:947-55. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
7. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67:11924-32. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
8. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-4. (Pubitemid 24107549)
9. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S: Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994, 9:1567-74. (Pubitemid 24163381)
10. Hallberg B, Palmer RH: Crizotinib-latest champion in the cancer wars? N Engl J Med 2010, 363:1760-2.
11. Palmer RH, Vernersson E, Grabbe C, Hallberg B: Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009, 420:345-61.
12. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8:11-23. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
13. Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, Kwee I, Bertoni F, Piccaluga PP, Pileri SA, Inghirami G; European T-Cell Lymphoma Study Group: Anaplastic lymphoma kinase (ALK) in human cancer. J Mol Endocrinol 2011, 47:R11-23. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
14. Murugan AK, Xing M: Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene. Cancer Res 2011, 71:4403-11. F1000 factor 7 Evaluated by Ruth Palmer 14 Oct 2011, Giancarlo Vecchio 01 Jun 2011, Barry Nelkin 25 May 2011
15. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-6. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
16. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-203. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
17. Du XL, Hu H, Lin DC, Xia SH, Shen XM, Zhang Y, Luo ML, Feng YB, Cai Y, Xu X, Han YL, Zhan QM, Wang MR: Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J Mol Med 2007, 85:863-75. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
18. Jazii FR, Najafi Z, Malekzadeh R, Conrads TP, Ziaee AA, Abnet C, Yazdznbod M, Karkhane AA, Salekdeh GH: Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006, 12:7104-12. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
19. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-8. F1000 Factor 9 Evaluated by Ruth Palmer 14 Oct 2011, Jenny Ting 04 Nov 2004.
20. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M; University of Hong Kong Lung Cancer Study Group: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115:1723-33. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
21. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ: Clinical features and outcome of patients with non-small- cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-53. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011, Antonella De Luca and Nicola Normanno 02 Nov 2009
22. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14:4275-83. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
23. Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, Engelman JA, Shyr Y, Khuri FR, Rudin CM, Garon EB, Pao W, Schiller JH, Haura EB, Shirai K, Giaccone G, Berry LD, Kugler K, Minna JD, Bunn PA: Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011, 29(Suppl): CRA7506.
24. Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y: Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features. Int J Clin Oncol 2011, 16:287-93. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
25. Suda K, Tomizawa K, Yatabe Y, Mitsudomi T: Lung cancers unrelated to smoking: characterized by single oncogene addiction? Int J Clin Oncol 2011, 16:294-305. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
26. Wong DW, Leung EL, Wong SK, Tin VP, Sihoe AD, Cheng LC, Au JS, Chung LP, Wong MP: A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 2011, 117:2709-18. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
27. Takeuchi, K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H: KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009, 15:3143-9. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
28. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA: The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-80. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
29. Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, Kamo T, Takamochi K, Suzuki K, Tanahashi M, Niwa H, Ogawa H, Sugimura H: EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 2008, 61:163-9. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
30. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P, Pastorino U, Carbone A, Fabbri A, Sidoni A, Nakamura S, Gambacorta M, Fernández PL, Ramirez J, Chan JK, Grigioni WF, Campo E, Pileri SA, Falini B: EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009, 174:661-70. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
31. Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M: EML4- ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer 2008, 98:1536-9. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
32. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008, 3:13-7. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
33. Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ, Beer DG, Rickman DS, Chinnaiyan AM, Moch H, Rubin MA: EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008, 10:298-302. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
34. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216-23. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
35. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding P, Liu Y, Sun F, Schultz PG, Gray NS, Warmuth M: Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 2007, 104:270-5. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
36. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6:3314-22. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
37. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, Haruta H, Hamada T, Yamashita Y, Ishikawa Y, Sugiyama Y, Mano H: A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008, 105:19893-7. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
38. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, Settleman J: Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008, 68:3389-95. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
39. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-703. F1000 Factor 6 Evaluated by Ruth Palmer 14 Oct 2011
40. Camidge DR, Bang Y, Kwak EL, Shaw AT, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Wilner KD, Costa DB, Shapiro G, LoRusso P, Stephenson P, Tang Y, Ruffner K, Clark JW: Progression-free survival (PFS) from a phase I study of crizotinib (PF- 02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl):2501.
41. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Iafrate AJ, Shapiro G, Costa DB, Butaney M, Ou SI, Maki RG, Bang Y, Varella-Garcia M, Salgia R, Wilner KD, Kulig K, Selaru P, Tang Y, Kwak EL, Clark JW, Camidge DR: Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. J Clin Oncol 2011, 29(Suppl):7507.
42. Bilsland JG, Wheeldon A, Mead A, Znamenskiy P, Almond S, Waters KA, Thakur M, Beaumont V, Bonnert TP, Heavens R, Whiting P, McAllister G, Munoz-Sanjuan I: Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 2008, 33:685-700. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
43. Bazigou E, Apitz H, Johansson J, Lorén CE, Hirst EM, Chen PL, Palmer RH, Salecker I: Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila. Cell 2007, 128:961-75. F1000 Factor 8 Evaluated by Talila Volk 20 Mar 2007
44. Vernersson E, Khoo NK, Henriksson ML, Roos G, Palmer RH, Hallberg B: Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr Patterns 2006, 6:448-61. (Pubitemid 43843121)
45. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM: Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-5. F1000 factor 7 Evaluated by Ruth Palmer 14 Oct 2011, Frans Van Roy 24 Sep 2008.
46. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-70. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
47. George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT: Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-8. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
48. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S: Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-4. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
49. Caren H, Abel F, Kogner P, Martinsson T: High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008, 416:153-9. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
50. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, Tanio Y, Mano H; ALK Lung Cancer Study Group: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363:1734-9.
51. Yun C. H., Mengwasser K. E., Toms A. V., Woo M. S., Greulich H., Wong K. K., Meyerson M., Eck M. J: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008, 105:2070-5. (Pubitemid 351439466)
52. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011, 108:7535-40. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
53. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y: CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant. Cancer Cell 2011, 19:679-90. F1000 factor 6 Evaluated by Ruth Palmer 14 Oct 2011
54. Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E, Gao MY, Hua S, Chen C, Kim S, Michellys PY, Lesley SA, Harris JL, Spraggon G: Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 2010, 430:425-37.
55. Bossi RT, Saccardo MB, Ardini E, Menichincheri M, Rusconi L, Magnaghi P, Orsini P, Avanzi N, Borgia AL, Nesi M, Bandiera T, Fogliatto G, Bertrand JA: Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 2010, 49:6813-25.
56. Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W: Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011, 71:4920-31.
57. Sabbatini P, Korenchuk S, Rowand JL, Groy A, Liu Q, Leperi D, Atkins C, Dumble M, Yang J, Anderson K, Kruger RG, Gontarek RR, Maksimchuk KR, Suravajjala S, Lapierre RR, Shotwell JB, Wilson JW, Chamberlain SD, Rabindran SK, Kumar R: GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther 2009, 8:2811-20.
58. Kruczynski A, Mayer P, Marchand A, Vispé S, Fournier E, Annereau JP, Brel V, Barret JM, Delsol G, Imbert T, Fahy J, Bailly C: Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase. Anticancer Drugs 2009, 20:364-72.
59. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita Y, Sugiyama Y, Ishikawa Y, Mano H: Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008, 68:4971-6.
60. Garcia-Echeverria C, Kanazawa T, Kawahara E, Masuya K, Matsuura N, Miyake T, Ohmori O, Umemura I, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding Q, Zhang Q, Gray NS, Karanewsky D: 2,4-Pyrimidinediamines useful in the treatment of neoplastic disease, inflammatory and immune system disorders. Novartis AG, Novartis Pharma 2005, GmbH, Patent number: WO/PCT 2005016894.
61. Ardini E, Menichincheri M, De Ponti C, Amboldi N, Saccardo MB, Texido G, Russo M, Orsini P, Bandiera T, Lombardi Borgia A, Isacchi A, Pesenti E, Colotta F, Magnaghi P, Galvani A; Nerviano Medical: Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models. Mol Cancer Ther 2009, 8(Suppl 1):A243.
62. Jake Slavish P, Jiang Q, Cui X, Morris SW, Webb TR: Design and synthesis of a novel tyrosine kinase inhibitor template. Bioorg Med Chem 2009, 17:3308-16.
63. Milkiewicz KL, Weinberg LR, Albom MS, Angeles TS, Cheng M, Ghose AK, Roemmele RC, Theroff JP, Underiner TL, Zificsak CA, Dorsey BD: Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem 2010, 18:4351-62.
64. Okamoto M, Kojima H, Saito N, Okabe T, Masuda Y, Furuya T, Nagano T: Virtual screening and further development of novel ALK inhibitors. Bioorg Med Chem 2011, 19:3086-95.
65. Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R: Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28:4953-60.
66. Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Adelmant GO, Capelletti M, Lee HJ, Rodig SJ, Borgman C, Park SI, Kim HR, Padera R, Marto JA, Gray NS, Kung AL, Shapiro GI, Jänne PA, Wong KK: Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010, 70:9827-36.
67. Li R, Morris SW: Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 2008, 28:372-412. (Pubitemid 351590540)
68. Milkiewicz KL, Ott GR: Inhibitors of anaplastic lymphoma kinase: a patent review. Expert Opin Ther Pat 2010, 20:1653-81.